These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 34256035)
1. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035 [TBL] [Abstract][Full Text] [Related]
2. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Lebwohl M; Strober B; Schrader A; Li AH; Eckmann T; Zhu B; Malatestinic WN; Birt J; Feely M; Blauvelt A Drugs Real World Outcomes; 2024 Sep; 11(3):451-464. PubMed ID: 38914857 [TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885 [TBL] [Abstract][Full Text] [Related]
4. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS). Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503 [TBL] [Abstract][Full Text] [Related]
5. Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities. Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS J Psoriasis Psoriatic Arthritis; 2023 Jan; 8(1):7-10. PubMed ID: 39296950 [TBL] [Abstract][Full Text] [Related]
6. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry. Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259 [TBL] [Abstract][Full Text] [Related]
7. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study. Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962 [TBL] [Abstract][Full Text] [Related]
8. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry. Yu C; Wang G; Burge RT; Ye E; Dou G; Li J; Harrison RW; McLean RR; Kerti SJ; Bagel J Dermatol Ther (Heidelb); 2023 Jan; 13(1):187-206. PubMed ID: 36385699 [TBL] [Abstract][Full Text] [Related]
10. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Kojanova M; Fialova J; Cetkovska P; Gkalpakiotis S; Jircikova J; Dolezal T; Arenberger P; Int J Dermatol; 2017 Apr; 56(4):428-434. PubMed ID: 28181669 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study. Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275 [TBL] [Abstract][Full Text] [Related]
12. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review. Xie Y; Liu Y Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472 [TBL] [Abstract][Full Text] [Related]
13. Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry. Enos CW; O'Connell KA; Harrison RW; McLean RR; Dube B; Van Voorhees AS J Psoriasis Psoriatic Arthritis; 2022 Jul; 7(3):122-131. PubMed ID: 39296532 [No Abstract] [Full Text] [Related]
14. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803 [TBL] [Abstract][Full Text] [Related]
15. History of diabetes is associated with reduced likelihood of achieving PASI75 and PASI90 at 12 months among psoriasis patients treated with biologics: A prospective analysis in the CorEvitas Psoriasis Registry. Enos CW; Maldonado YM; Kang HJ; McLean RR; Van Voorhees AS JAAD Int; 2024 Sep; 16():237-238. PubMed ID: 39072265 [No Abstract] [Full Text] [Related]
16. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Maul JT; Djamei V; Kolios AGA; Meier B; Czernielewski J; Jungo P; Yawalkar N; Mainetti C; Laffitte E; Spehr C; Anliker M; Streit M; Augustin M; Rustenbach S; Conrad C; Hafner J; Boehncke WH; Borradori L; Gilliet M; Itin P; French LE; Häusermann P; Navarini AA Dermatology; 2016; 232(6):640-647. PubMed ID: 28076860 [TBL] [Abstract][Full Text] [Related]
18. Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry. McLean RR; Sima AP; Beaty S; Jones EA; Eckmann T; Low R; McClung L; Spitzer RL; Stark J; Armstrong A Dermatol Ther (Heidelb); 2023 Nov; 13(11):2753-2768. PubMed ID: 37759099 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528 [TBL] [Abstract][Full Text] [Related]
20. Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States. Enos CW; O'Connell KA; Harrison RW; McLean RR; Dube B; Van Voorhees AS JID Innov; 2021 Jun; 1(2):100025. PubMed ID: 34909720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]